跳至主要内容
临床试验/NCT06017362
NCT06017362招募中4 期

Ensayo Clínico Para Determinar La Eficacia Y Seguridad Del Colirio De Insulina En El Tratamiento Del Ojo Seco En Pacientes Con Hipotensores Tópicos

Barbara Burgos Blasco1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年2月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Changes in dry eye symptoms from baseline to 6 months after treatment time

研究概览

简要总结

The goal of this clinical trial is to evaluate the preliminary efficacy of the use of insulin eye drops in the control of dry eye disease in patients with topical hypotensors, compared to placebo (artificial tears).

The main question aims to answer whether glaucoma patients treated with topical hypotensors could benefit from the use of insulin eye drops for the treatment of dry eye.

Participants will be assigned to one of the two treatment arms and will be required to attend four follow-up visits (baseline, 1, 3, and 6 months).

详细描述

Patients will be recruited in Madrid. Patients with dry eye disease and topical glaucoma treatment will be identified through the Ophthalmology clinic. They will be directly referred to a physician who is participating in this study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who provide written informed consent and who are able and willing to comply with all scheduled study visits and procedures.
  • Patients ≥ 18 years at the screening visit.
  • Ocular hypertension or glaucoma controlled with hypotensive treatment
  • Diagnosis of dry eye

排除标准

  • Uncontrolled glaucoma with expected changes in antihypertensive treatment in the next 6 months
  • Changes in topical glaucoma treatment in the last 3 months
  • Severe dry eye requiring immediate treatment
  • Previous eye surgery, except cataract surgery more than 12 months ago
  • Laser procedures less than 6 months ago
  • Other concomitant ocular pathology: scarring disease of the ocular surface, uveitis, infection in the last 90 days, trauma in the last 90 days
  • Eyelid disorders
  • Use of contact lenses
  • Other topical treatment other than dry eye and glaucoma
  • Patients with a history of allergy or hypersensitivity to the study medication or any of its excipients
  • Modifications in systemic immunosuppressive treatment in the last 6 months
  • History of alcohol or drug abuse
  • Patients who have received an experimental drug or used an experimental medical device in the 30-day period prior to the screening visit.
  • Systemic pathology (cardiopulmonary pathology, connective tissue disorders, neurological or psychiatric pathology) or situation of the patient that does not allow examination (such as mental or psychomotor retardation).
  • Any other disease or condition that, at the discretion of the investigator, could constitute a risk to the participant or interfere with the results of the study.

研究组 & 干预措施

Insulin

Experimental

Topical insulin 1UI/ml 4 times a day

干预措施: Insulin (Drug)

Placebo (artificial tears)

Placebo Comparator

Artificial tears 4 times a day

干预措施: Artificial tear (Drug)

结局指标

主要结局

Changes in dry eye symptoms from baseline to 6 months after treatment time

时间窗: From baseline to 6 months after treatment

Dry eye symptoms will be evaluated using OSDI

次要结局

  • Change of corneal staining from baseline to 6 months after treatment(From baseline to 6 months after treatment)
  • Change in corneal aesthesiometry from baseline to 6 months after treatment(From baseline to 6 months after treatment)
  • Change in conjunctival hyperemia from baseline to 6 months after treatment(From baseline to 6 months after treatment)
  • Change in non-invasive tear film break-up time from baseline to 6 months after treatment(From baseline to 6 months after treatment)
  • Change in light dispersion from baseline to 6 months after treatment(From baseline to 6 months after treatment)
  • Change in cytokine levels from baseline to 6 months after treatment(From baseline to 6 months after treatment)
  • Change in therapeutic compliance from baseline to 6 months after treatment(From baseline to 6 months after treatment)

研究者

发起方
Barbara Burgos Blasco
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Barbara Burgos Blasco

Principal Investigator

Hospital San Carlos, Madrid

研究点 (1)

Loading locations...

相似试验